. 2014 Feb 6;10(6):1514–1521. doi: 10.4161/hv.27796

Table 1. Efficacy of the native and recombinant Gal-lectin vaccine trials.

Antigen	Form^a	Adjuvant/ Delivery	Route^b	Dose of antigen (μg)	% Protective efficacy^c	Ref.
260-kDa	Native	Freund’s	s.c. i.p.	Wk 0, 2, 4: 10 Wk 0, 2, 4: 10	43-67 ALA 86 ALA	35
260-kDa**	Native	CTB Freund’s	i.n. i.p.	Wk 0, 2, 6, 7, 9: 10 Wks 4, 7: 15	100 AC	63
260-kDa**	Native	CpG-ODN	i.n. i.p.	Wk 0, 1, 3, 5: 10 Wk 5: 10	100 ALA	42
260-kDa	Native	EhDNA	i.m.	Wk 0, 1, 2: 10	100 ALA	64
aa 1-1204*	Recombinant	Yersinia enterocolitica	Orally	Wk 0, 1, 2, 3, 4: 10⁹	3-68 ALA	65
aa 1-436 aa 436-624 aa 799-939 aa 939-1053	Recombinant	Freund’s	i.p.	Wk 0, 2, 4: 50	6.7 ALA 37.5 ALA 11.1 ALA 62.5 ALA	41
aa 482-1138	Recombinant His tagged Recombinant	Freund’s Salmonella dublin	i.p. Orally	Wk 0, 4: 30 Days 1, 5, 7: 10⁸-10¹⁰	45 ALA 18-28 ALA	66
aa 578-1154**	Recombinant	CTB Freund’s	i.n. i.p.	Wk 0, 2, 6, 7, 9: 10 Wk 4:15	34–89 AC	63
aa 649-1201	Recombinant GST fusion	Freund’s	i.p.	Wk 0, 4, 7: 150	81 ALA	67
aa 758-1134	Recombinant His tagged	Titermax	i.p.	Wk 0, 2, 4: 10	71 ALA	36
aa 895-998	Recombinant His tagged	Freund’s	i.p.	Wk 0, 2: 200 Wk 4: 400	N/A	68
aa 1005-1029 aa 1005-1029* aa 1005-1029*	Synthetic peptide, KLH fusion Recombinant CTB fusion Recombinant CTB fusion	Freund’s None Freund’s	i.p. Orally i.p.	Wk 0, 2, 4: 50 Wk 0, 2, 4, 13: 100 Wk 0, 2, 4: 50	33 ALA 0-30 ALA 0-55 ALA	69

aa, amino acid; CTB, cholera toxin b; ALA, amebic liver abscess; AC, amebic colitis; Wks, weeks; Cysteine-poor domain, aa 1–436; Pseudo-repeat domain, 436–624; Cysteine-rich domain, 624–1053. *Varying fragments of residues within this region. **Experiments with combined regimens. ^aAll recombinant proteins were produced in Escherichia coli. ^bRoutes: i.p., intraperitoneally; i.n., intranasally; i.m., intramuscularly; s.c, subcutaneously; orally, by oral gavage. ^c%Protective Efficacy: ([number of unvaccinated animals infected-number of vaccinated animals infected]/[number of unvaccinated animals infected]) × 100.